Table 2.

Parameters inferred from the models

Data	Growth model	Location	Par.	Unit	Estimate (CV)	95 % CI
In vitro (Breast)	Exp.		λ	day−1	0.837 (−)	(0.795 – 0.879)
Preclinical Breast	Gomp-Exp.	PT	Vi	cell	1.00 × 106 (−)	-
			α	day−1	1.9 (5.73)	(1.84 – 1.96)
			β	day−1	0.0893 (21.3)	(0.0791 – 0.101)
		Met	V0	p/s	10 (−)	-
			μ	cell−1 · day−1	4.43 × 10−11 (176)	(2.70 × 10−11 – 7.27 × 10−11)
Preclinical Kidney	Exp.	PT	Vi	p/s	1.63 × 105 (45.5)	(9.40 × 104 – 2.83 × 105)
			αp	day−1	0.21 (60.3)	(0.151 – 0.292)
		Met	V0	p/s	10 (−)	-
			α	day−1	0.0307 (201)	(0.0133 – 0.0707)
			μ	cell−1 · day−1	0.0415 (397)	(0.0181 – 0.0948)
Clinical Breast	Gomp.	PT	Vi	cell	1 (−)
			α	day−1	0.013 (−)
			β	day−1	0.000471 (−)
		Met	V0	cell	1 (−)
			μ	cell−1 · day−1	7.00 × 10−12 (1.04 × 104)

Parameters corresponding to the preclinical data were obtained using nonlinear mixed-effects modeling. Inter-animal variability of each parameter is captured by its respective coefficient of variation (CV). Parameter values for the clinical data are those that produced the fit to the clinical data of metastatic relapse probability from (26), reported in Table 1. For these data, only parameter μ was allowed to vary between the individuals in this setting and consequently it is the only parameter having a coefficient of variation (CV). $\text{CV}=\text{Coefficient}\text{of}\text{Variation}\text{in}\text{percent}=\frac{\mathit{std}}{\mathit{est}}\times 100$, with std the standard deviation of the lognormal distribution of the parameter and est the population estimate.

CI = Confidence Interval on the population estimate inferred from the standard errors on the fit.